S11 Ep21: Updated VISION Trial Data Showcase The Efficacy Of Tepotinib In MET + NSCLC: With Martin Dietrich, MD OncLive® On Air podcast

Artwork

Fitness Audioboom OncLive® On Air Oncology Science Medicine Exclusive Interviews

Innhold levert av Audioboom and OncLive® On Air. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Audioboom and OncLive® On Air eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

OncLive® On Air « »
S11 Ep21: Updated VISION Trial Data Showcase the Efficacy of Tepotinib in MET + NSCLC: With Martin Dietrich, MD

3d ago 11:59

Del

MP3•Episoder hjem

Innhold levert av Audioboom and OncLive® On Air. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Audioboom and OncLive® On Air eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

In our exclusive interview, Dr Dietrich discussed key efficacy findings from the 18-month follow-up of the phase 2 VISION trial (NCT02864992), which evaluated the efficacy of tepotinib (Tepmetko) in patients with non–small cell lung cancer harboring MET exon 14 skipping mutations. Additionally, Dr Dietrich emphasized important safety considerations with tepotinib, particularly the management of on-target adverse effects (AEs) like edema. He also discussed strategies for addressing treatment-related AEs, such as hyperalbuminemia, hyponatremia, and kidney function abnormalities, and highlighted the importance of careful monitoring to make dose adjustments as necessary.

… continue reading

534 episoder

#Fitness #Audioboom #OncLive® On Air #Oncology #Science #Medicine #Exclusive Interviews

Artwork

S11 Ep21: Updated VISION Trial Data Showcase the Efficacy of Tepotinib in MET + NSCLC: With Martin Dietrich, MD

OncLive® On Air

29 subscribers

published 3d ago

Del

MP3•Episoder hjem

Innhold levert av Audioboom and OncLive® On Air. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Audioboom and OncLive® On Air eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

In our exclusive interview, Dr Dietrich discussed key efficacy findings from the 18-month follow-up of the phase 2 VISION trial (NCT02864992), which evaluated the efficacy of tepotinib (Tepmetko) in patients with non–small cell lung cancer harboring MET exon 14 skipping mutations. Additionally, Dr Dietrich emphasized important safety considerations with tepotinib, particularly the management of on-target adverse effects (AEs) like edema. He also discussed strategies for addressing treatment-related AEs, such as hyperalbuminemia, hyponatremia, and kidney function abnormalities, and highlighted the importance of careful monitoring to make dose adjustments as necessary.

… continue reading

534 episoder

#Fitness #Audioboom #OncLive® On Air #Oncology #Science #Medicine #Exclusive Interviews

Tất cả các tập

×

Velkommen til Player FM!

Player FM scanner netter for høykvalitets podcaster som du kan nyte nå. Det er den beste podcastappen og fungerer på Android, iPhone og internett. Registrer deg for å synkronisere abonnement på flere enheter.

Lytt til 500+ tema